Evaluation of BACTEC MGIT 960 system for the second-line drugs susceptibility testing of Mycobacterium tuberculosis in China

Journal of Microbiological Methods

Volumn 91, Issue 1, 2012, Pages 212-214

  Zhao, Li li ^a   Xia, Qiang ^b   Lin, Nan ^c,d   Liu, Binbin ^a,e   Zhao, Xiu qin ^a   Liu, Zhiguang ^a   Wan, Kang lin ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Zhejiang Prevention and Treatment Center of Tuberculosis   (China)

^c INSTITUTE OF BIOPHYSICS   (China)

^d FUJIAN AGRICULTURE AND FORESTRY UNIVERSITY   (China)

^e CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

BACTEC MGIT 960 system; Drug susceptibility testing; L J media; Mycobacterium tuberculosis; The proportion method; The second line drugs

Indexed keywords

CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHINA; CONTROLLED STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROPORTION METHOD; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; TURNAROUND TIME;

ANTITUBERCULAR AGENTS; CHINA; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TIME FACTORS; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84867647586     PISSN: 01677012     EISSN: 18728359     Source Type: Journal    
DOI: 10.1016/j.mimet.2012.06.010     Document Type: Article

References (17)

1. Altman D.G. Inter-rater Agreement. Practical Statistics for Medical Research 1999, 403-409. Chapman & Hall/CRC, London. D.G. Altman (Ed.).
2. Canetti G., Fox W., Khomenko A., Mahler H.T., Menon N.K., Mitchison D.A., Rist N., Smelev N.A. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull. World Health Organ. 1969, 41(1):21-43.
3. Golyshevskaia V.I., Irtuganova O.A., Smirnova N.S., Domotenko L.V. Comparison of nitrate reductase and automatic BACTEC MGIT 960 AST techniques for determining the drug sensitivity of mycobacteria tuberculosis. Probl. Tuberk. Bolezn. Legk. 2003, 8:34-37.
4. Huang T.S., Tu H.Z., Lee S.S., Huang W.K., Liu Y.C. Antimicrobial susceptibility testing of Mycobacterium tuberculosis to first-line drugs: comparisons of the MGIT 960 and BACTEC 460 systems. Ann. Clin. Lab. Sci. 2002, 32(2):142-147.
5. Johansen I.S., Thomsen V.O., Marjamaki M., Sosnovskaja A., Lundgren B. Rapid, automated, nonradiometric susceptibility testing of Mycobacterium tuberculosis complex to four first-line antituberculous drugs used in standard short-course chemotherapy. Diagn. Microbiol. Infect. Dis. 2004, 50(2):103-107.
6. Kobayashi I., Abe C., Mitarai S. BACTEC MGIT 960 system for drug susceptibility testing of Mycobacterium tuberculosis: a study using external quality assessment strains. Kekkaku 2006, 81(2):57-62.
7. Kontos F., Maniati M., Costopoulos C., Gitti Z., Nicolaou S., Petinaki E., Anagnostou S., Tselentis I., Maniatis A.N. Evaluation of the fully automated Bactec MGIT 960 system for the susceptibility testing of Mycobacterium tuberculosis to first-line drugs: a multicenter study. J. Microbiol. Methods 2004, 56(2):291-294.
8. Kruuner A., Yates M.D., Drobniewski F.A. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J. Clin. Microbiol. 2006, 44(3):811-818.
9. Lin S.Y., Desmond E., Bonato D., Gross W., Siddiqi S. Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. J. Clin. Microbiol. 2009, 47(11):3630-3634.
10. Morcillo N., Imperiale B., Di Giulio B. Evaluation of MGIT 960 and the colorimetric-based method for tuberculosis drug susceptibility testing. Int. J. Tuberc. Lung Dis. 2010, 14(9):1169-1175.
11. Rodrigues C., Jani J., Shenai S., Thakkar P., Siddiqi S., Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. Int. J. Tuberc. Lung Dis. 2008, 12(12):1449-1455.
12. Rusch-Gerdes S., Pfyffer G.E., Casal M., Chadwick M., Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J. Clin. Microbiol. 2006, 44(3):688-692.
13. Sharma M., Thibert L., Chedore P., Shandro C., Jamieson F., Tyrrell G., Christianson S., Soualhine H., Wolfe J. Canadian multicenter laboratory study for standardized second-line antimicrobial susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 2011, 49(12):4112-4116.
14. Tomita M., Takeno H., Suzuki K., Sakatani M., Kinoshita Y., Kobayashi I. A study on inoculum density and reproducibility of drug susceptibility testing by BACTEC MGIT 960. Kekkaku 2004, 79(11):625-630.
15. van Ingen J., Simons S., de Zwaan R., van der Laan T., Kamst-van Agterveld M., Boeree M.J., van Soolingen D. Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 2010, 48(8):2749-2753.
16. WHO Policy guidance on TB drug susceptibility testing (DST) of second-line drugs 2008, WHO, Geneva, WHO/HTM/TB/2008392.
17. World Health Organization Global tuberculosis control: surveillance p, financing. WHO report 2008 2008, The Organization, Geneva, WHO/HTM/TB/2008.393.